In 2019, the Centers for Medicare & Medicaid Services (CMS) directed the Texas Health and Human Services Commission (HHSC) to update Texas Medicaid long-term services and supports (LTSS) billing codes to comply with the National Correct Coding Initiative (NCCI) by...
Beginning Sept. 1, 2022, Texas Medicaid will designate one medication as the primary preferred direct-acting antiviral (DAA) drug option for treating Hepatitis C infection. HHSC will designate all other DAA drugs on the Medicaid formulary as non-preferred. All...
